| Lars Rebien Sørensen |
Lars Rebien Sørensen currently works at Novo Nordisk Fonden, as Chairman from 2018, Ferring Pharmaceuticals A, as Vice Chairman from 2023, Ferring Holding SA, as Vice Chairman from 2024, Ferring International Center SA, as Chairman-Supervisory Board from 2021, Novo Holdings A, as Chairman from 2018, and Novo Nordisk A, as Chairman from 2025. Mr. Sørensen also formerly worked at Novo Nordisk A, as President & Chief Executive Officer from 2000 to 2017, Novo Nordisk (Private Equity), as Chief Executive Officer from 2001 to 2014, Carlsberg A, as Deputy Chairman-Supervisory Board from 2015 to 2019, Carlsberg Breweries A, as Chairman-Supervisory Board from 2015 to 2019, Novo Holdings A, as Chairman from 2018 to 2025, Thermo Fisher Scientific, Inc., as Independent Director from 2016 to 2024, ZymoGenetics, Inc., as Director from 1996 to 2010, Svenska Cellulosa AB SCA, as Director, Danmarks Nationalbank, as Director, Ørsted A, as Director, Cameron Services AG, as Director, Thermo Fisher Scientific, Inc., as Independent Director from 2012 to 2015, Essity AB, as Independent Director, Novo Nordisk A, as Director, Bertelsmann SE & Co. KGaA, as Member-Supervisory Board from 2005 to 2015, the University of Copenhagen, as Professor, Bertelsmann Management SE, as Member-Supervisory Board, and Essity Germany GmbH, as Member-Supervisory Board. Mr. Sørensen received his undergraduate degree in 1983 from Copenhagen Business School and graduate degree in 1981 from the University of Copenhagen. |
| Karsten Munk Knudsen |
Karsten Munk Knudsen currently works at NNE A, as Chairman, Novo Nordisk Region AAMEO & LATAM A, as Chairman, Novo Nordisk Region Europe A, as Chairman, Novo Nordisk North America Operations A, as Chairman, 3shape Holding A, as Director from 2023, Hempel A, as Director from 2021, and Novo Nordisk A, as Chief Financial Officer & Executive Vice President from 2018. Mr. Knudsen also formerly worked at A.P. Møller-Mærsk A, as Principal, Nykredit Bank A, as Financial Analyst, Innate Pharma SA, as Member-Supervisory Board, Novo Nordisk, Inc., as VP-Finance & Information Technology from 2010 to 2014, and NNIT A, as Head-Finance. Mr. Knudsen received his graduate degree in 1998 from the University of Aarhus. |
| Maziar Mike Doustdar |
Mr. Maziar Mike Doustdar is an Independent Director at Orion Oyj, a President & Chief Executive Officer at Novo Nordisk A/S and a Managing Director at Novo Nordisk Health Care AG. He is on the Board of Directors at Orion Oyj. Mr. Doustdar was previously employed as a Member by European Federation of Pharmaceutical Industries & Assns and an EVP & Head-International Operations by Novo Nordisk Ltd. He received his undergraduate degree from Webster University. |
| Liselotte Hyveled |
Liselotte Hyveled currently works at Novo Nordisk A, as Non-Independent Director & Chief Patient Officer and RSP Systems A, as Director. Ms. Hyveled also formerly worked at Novo Nordisk A, as Director from 2014 to 2018 and TriSalus Life Sciences, Inc., as Independent Director from 2024 to 2025. Ms. Hyveled received her graduate degree in 2011 from Copenhagen Business School and graduate degree in 1992 from the University of Copenhagen. |
| Stephen Gough |
Stephen Gough has worked as the Global Chief Medical Officer at Novo Nordisk A since 2015. |
| Martin Holst Lange |
Martin Holst Lange currently works at Pharmacosmos A, as Director from 2023 and Novo Nordisk A, as Chief Scientific Officer & Executive VP from 2025. Dr. Lange also formerly worked at Novo Nordisk, Inc., as Medical Director from 2006 to 2008 and Beta Bionics, Inc., as Director from 2017 to 2020. Dr. Lange received his doctorate degree in 1997 from the University of Copenhagen and doctorate degree in 2004 from the University of Copenhagen. |
| Thilde Hummel Bogebjerg |
Thilde Hummel Bogebjerg currently works at Novo Nordisk A, as Executive VP-Quality, IT & Environmental Affairs from 2025. Mr. Bogebjerg received his undergraduate degree in 2007 from Technical University of Denmark. |
| Henrik Ehlers Wulff |
Henrik Ehlers Wulff currently works at Novo Nordisk Production SAS, as Chairman, Novo Nordisk Pharmatech A, as Chairman, Grundfos Americas Corp., as Director, Grundfos Holding A, as Director from 2021, and Novo Nordisk A, as Executive Vice President-Product Supply from 2025. Mr. Wulff also formerly worked at NNE A, as Director, NNE Pharmaplan A, as Director, and Ambu A, as Independent Director. Mr. Wulff received his graduate degree in 1995 from Technical University of Denmark. |
| Filip Krag Knop |
Filip Krag Knop started working at Novo Nordisk A in 2025. The role held is Chief Medical Officer, beginning in 2025 and continuing currently. |
| Helge Lund |
Helge Lund currently works at BP Canada Energy Group ULC, as Chairman from 2019, Novo Nordisk A, as Chairman from 2018, BP Oil Australia Pty Ltd., as Chairman from 2018, Inkerman Holding AS, as Chairman, Tjaldur P, as Non-Executive Director, Belron Group SA, as Director, International Crisis Group, as Trustee, European Round Table of Industrialists, as Member, BP Technology Ventures Ltd., as Chair of the Board from 2019, and The International Crisis Group (United States), as Trustee. Mr. Lund also formerly worked at BG Group Ltd., as Chief Executive Officer & Executive Director from 2015 to 2016, Equinor ASA, as President & Chief Executive Officer from 2004 to 2014, Schlumberger GmbH, as Chief Executive Officer-Oil Services, Akastor ASA, as President & Chief Executive Officer from 2002 to 2004, BP America, Inc., as Chairman, BP Plc, as Chairman from 2019 to 2025, Nokia Oyj, as Independent Non-Executive Director from 2012 to 2014, SLB Ltd., as Independent Non-Executive Director from 2016 to 2018, Novo Nordisk A, as Independent Director from 2014 to 2015, D'IM SA, as Director, Takeda AS, as Deputy Managing Director, and Novo Nordisk Ltd., as Director. Mr. Lund received his Masters Business Admin degree in 1991 from INSEAD and graduate degree in 1987 from Norwegian School of Economics & Business Administration. |
| Lars Fruergaard Jørgensen |
Lars Fruergaard Jørgensen currently works at Novo Nordisk A, as President & Chief Executive Officer from 2017, Danmarks Nationalbank, as Director, European Federation of Pharmaceutical Industries & Assns, as President from 2021, and Federation Européenne D'Associations Et D'Industries Pharma, as President. Mr. Jørgensen also formerly worked at Carlsberg A, as Vice Chairman-Supervisory Board, Carlsberg Breweries A, as Vice Chairman-Supervisory Board, NNE Pharmaplan A, as Vice Chairman, Harno Invest A, as Chairman, ZymoGenetics, Inc., as Director in 2010, NNIT A, as Director from 2005 to 2015, Innate Pharma SA, as Member-Supervisory Board from 2007 to 2013, and Novo Nordisk SAS, as Vice President-Finance & Information Technology in 2004. Mr. Jørgensen received his graduate degree in 1989 and Masters Business Admin degree in 1991 from the University of Aarhus. |
| Martin W. MacKay |
Martin W. MacKay was the founder of Rallybio LLC, founded in 2018, serving as Executive Chairman & Chief Executive Officer until 2023. Dr. MacKay is the founder of Rallybio Corp., founded in 2018, currently holding the title of Chairman. Current jobs include Chief Executive Officer at Calyx Group Ltd. (Ireland), Chief Executive Officer & Director at Rallybio Holdings LLC, Lead Independent Director at Charles River Laboratories International, Inc. starting in 2025, Independent Director at Charles River Laboratories, Inc., and Independent Director at Novo Nordisk A since 2018. Former jobs include Chief Executive Officer at Vecta Software Corp. Ltd., Chief Executive Officer at Neverfail, Inc. in 2012, Chief Executive Officer & Director at Neverfail Ltd., Director at Encysive Pharmaceuticals, Inc. in 2008, Operations Director at The Dun & Bradstreet Corp., Director-Business Development at NorthgateArinso, Inc., Independent Director at Springworks Therapeutics, Inc. from 2024 to 2025, Independent Director at 5:01 Acquisition Corp. from 2020 to 2022, President-Global Research & Development at AstraZeneca PLC from 2010 to 2013, Global Head-Research & Development at Alexion Pharmaceuticals, Inc. from 2013 to 2017, Vice President-International at VeriSign, Inc., Head-Drug Preformulation & Delivery at BASF Performance Products Ltd. (United Kingdom), Senior Advisor at New Leaf Venture Partners LLC, President at Pfizer (St. Louis), Head-Molecular & Cell Biology at CRI Worldwide LLC in 1995, Principal at PeopleSoft USA, Inc., Principal at Accenture LLC, Head-Drug Preformulation & Delivery at Ciba-Geigy Pharmaceuticals from 1986 to 1995, Principal at Beecham Pharmaceuticals (UK), and Senior Vice President-Worldwide Development at Pfizer Inc. from 1995 to 2010. Education includes a doctorate from The University of Edinburgh, conferred in 1984, and an undergraduate degree from Heriot-Watt University, conferred in 1979. |
| Laurence Debroux |
Ms. Laurence Debroux is an Independent Director at Novo Nordisk A/S, an Independent Non-Executive Director at EXOR NV and a Chief Financial Officer & Director at Dibevit Import Srl. She is on the Board of Directors at Randstad NV, Kite Insights Ltd., Novo Nordisk A/S, EXOR NV, École des Hautes Études Commerciales de Paris, Bpifrance Participations SA, JCDecaux Bollore Holding SAS, Dibevit Import Srl and Institut Mérieux SA. Ms. Debroux was previously employed as an Independent Director by Solvay SA, a Chief Financial Officer & Director by Heineken NV, a Chief Financial Officer by Heineken Holding NV, a Member-Supervisory Board by MediaKiosk SAS, a Chief Financial & Administrative Officer by JCDecaux SA, an Independent Director by Natixis SA, and a Chief Financial & Strategic Officer by Sanofi SA. She also served on the board at Média Aéroports de Paris SAS, APG SGA SA and Juventus Football Club SpA. She received her graduate degree from École des Hautes Études Commerciales de Paris. |
| Andreas Fibig |
Andreas Fibig currently works at Max Planck Institute For Infection Biology, as Chairman, Novo Nordisk A, as Independent Director from 2018, ExlService Holdings, Inc., as Independent Director from 2023, World Business Council for Sustainable Development, as Executive Director, European Federation of Pharmaceutical Industries & Assns, as Director, German American Chamber of Commerce, Inc., as Honorary Director from 2021, Indigo Ag, Inc., as Director from 2022, Montai Health, Inc., as Director from 2023, Evodiabio ApS, as Director from 2022, and German Academy of New York, as Member. Mr. Fibig also formerly worked at International Flavors & Fragrances, Inc., as Chairman & Chief Executive Officer from 2014 to 2022, Bayer Pharma AG, as Chairman from 2008 to 2014, Bayer HealthCare Pharmaceuticals, Inc., as President & Chairman-Management Board from 2008 to 2014, Bayer Schering Pharma AG, as Director-Sales & Marketing in 1984, Bunge Ltd., as Independent Director from 2016 to 2018, Council of the Americas, Inc., as Director, Pfizer Inc., as Senior VP-US Pharmaceutical Operations Group from 2007 to 2008, Boehringer Ingelheim GmbH, as Principal in 2000, Pharmacia GmbH, as President-Market from 2000 to 2003, and Verband Forschender Arzneimittelhersteller eV, as Member-Supervisory Board. Mr. Fibig received his undergraduate degree in 1982 from Hochschule für Wirtschaft und Recht Berlin. |
| Sylvie Louise Grégoire |
Sylvie Louise Grégoire is the founder of EIP Pharma, Inc. since 2010, holding the title of Executive Chairman. Dr. Grégoire is the founder of CervoMed, Inc. since 1995, holding the title of Director. Current jobs include Chairman at Abivax SA since 2024, Independent Director at Novo Nordisk A since 2015, Director at F2G Ltd. since 2021, and Member-Supervisory Board at Shire Orphan Therapies GmbH. Former jobs include President, CEO & Executive Director at GlycoFi, Inc. from 2004 to 2005, Chairman at MetrioPharm AG, Executive Chairman at Takeda Pharmaceutical Co., Ltd. from 2006 to 2007, Chairman at Corvidia Therapeutics, Inc. from 2016 to 2020, Independent Director at Cubist Pharmaceuticals LLC from 2006 to 2011, Director at Thallion Pharmaceuticals, Inc., Director at CellCarta Biosciences, Inc., Director at Vifor Pharma Management AG, Director at Novo Nordisk Ltd., Director at Galenica AG, Director at Revvity, Inc., Non-Executive Director at Corden Pharma Fribourg SA from 2013 to 2019, Director at IDM Pharma, Inc. from 2005 to 2008, Independent Director at Revvity, Inc. from 2015 to 2024, Executive Vice President-Technical Operations at Biogen MA, Inc. from 2001 to 2003, Executive Vice President-Business Development at Biogen, Inc. from 2001 to 2003, President at Shire Human Genetic Therapies, Inc. from 2007 to 2013, and President-Human Genetic Therapies Division at Shire Plc from 2007 to 2013. Education includes a doctorate from State University of New York at Buffalo in 1986, an undergraduate degree from Université Laval in 1984, and an undergraduate degree from Séminaire de Sherbrooke in 1980. |
| Christina Law |
Ms. Christina Law is an Independent Director at Air Liquide SA, an Independent Director at Novo Nordisk A/S and a Group Chief Executive Officer & Director at Raintree Group Ltd. She is on the Board of Directors at National Gallery Singapore, Air Liquide SA, Novo Nordisk A/S, Greenfields Dairy Singapore Pte Ltd., Raintree Group Ltd., Raintree Investment Pte Ltd., Insead Business School and La Fondation Des Champions. Ms. Law was previously employed as an Independent Director by Air Liquide Tunisie SA, a Group President-Asia & Latin America by General Mills, Inc., a Head-Marketing by Proctor & Gamble, a Regional Director-Baby Care by Johnson & Johnson, and a Manager-Chemical Division by Shell Hong Kong Ltd. She received her undergraduate degree from The University of Hong Kong and an MBA from INSEAD. |
